Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer reported seven-year follow-up results from the Phase 3 CROWN trial for LORBRENA in ALK-positive advanced NSCLC. Patients treated with LORBRENA had a 55% likelihood of remaining alive without disease progression at seven years, compared to 3% for the XALKORI comparator arm. Median progression-free survival was not reached for LORBRENA, representing an 81% reduction in the risk of disease progression or death versus XALKORI.
Key figures
- Drug Name
- LORBRENA (lorlatinib)
- Phase Of Trial
- Phase 3
- Hazard ratio pfs
- 0.19
- Pfs likelihood 7yr
- 55%
- Risk reduction pfs
- 81%
- Grade 3 4 aes xalkori
- 57%
- Grade 3 4 aes lorbrena
- 77%
- Patients on treatment 7yr
- 44%
- Patients on comparator 7yr
- 3%
- Hazard ratio ic progression
- 0.06
- Discontinuation rate xalkori
- 6%
- Discontinuation rate lorbrena
- 5%
- Pfs likelihood 7yr comparator
- 3%
- Risk reduction ic progression
- 94%
- Median time ic progression comparator
- 16.4 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.